Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors.
This study is a single-arm, prospective, single-center clinical study of pyrotinib plus
fulvestrant as the therapy HR+/HER2+ metastatic breast cancer.